期刊论文A microfluidic bone marrow chip for the safety profiling of biologics in pre-clinical drug development复制

DOI:复制

文献链接:复制

其他信息:

L Koenig, L Juglair, TP Tao, S Fischer…
Communications …, 2025
nature.com
Hematologic adverse events are common dose-limiting toxicities in drug development. Classical animal models for preclinical safety assessment of immunotherapies are often limited due to insufficient cross-reactivity with non-human homologous proteins, immune system differences, and ethical considerations. Therefore, we evaluate a human bone marrow (BM) microphysiological system (MPS) for its ability to predict expected hematopoietic liabilities of immunotherapeutics. The BM-MPS consists of a closed …